http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 12 Aug 2026 16:24:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DiaMedica+Therapeutics++++For%3A+Aug+10++Filed+by%3A+Pauls+Dietrich+John/26913309.html si-local-file:///var/storage/secattach/20260812/26913309.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DiaMedica+Therapeutics++++For%3A+Aug+10++Filed+by%3A+Pauls+Dietrich+John/26913309.html Wed, 12 Aug 2026 16:24:00 -0400 DMAC O.02595765 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DiaMedica+Therapeutics++++For%3A+Aug+10++Filed+by%3A+Pauls+Dietrich+John/26913309.html si-local-file:///var/storage/secattach/20260812/26913309.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DiaMedica+Therapeutics++++For%3A+Aug+10++Filed+by%3A+Pauls+Dietrich+John/26913309.html Wed, 12 Aug 2026 16:24:00 -0400 DMAC O.02595765 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DiaMedica+Therapeutics+++++++++++++++/26902256.html si-local-file:///var/storage/secattach/20260811/26902256.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DiaMedica+Therapeutics+++++++++++++++/26902256.html Tue, 11 Aug 2026 08:45:00 -0400 DMAC O.02595765 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DiaMedica+Therapeutics+++++++++++++++/26902256.html si-local-file:///var/storage/secattach/20260811/26902256.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DiaMedica+Therapeutics+++++++++++++++/26902256.html Tue, 11 Aug 2026 08:45:00 -0400 DMAC O.02595765 http://www.streetinsider.com/Earnings/DiaMedica+Therapeutics+Inc.+%28DMAC%29+Reports+In-Line+Q2+EPS/26899374.html <p>DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.19), in-line with the analyst estimate of ($0.19).</p><p>For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) <a href="http://www.streetinsider.com/ec_earnings.php?q=DMAC">click here</a>.</p> http://www.streetinsider.com/Earnings/DiaMedica+Therapeutics+Inc.+%28DMAC%29+Reports+In-Line+Q2+EPS/26899374.html Mon, 10 Aug 2026 17:36:42 -0400 DMAC http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DiaMedica+Therapeutics++++For%3A+Jun+30/26898650.html si-local-file:///var/storage/secattach/20260810/26898650.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DiaMedica+Therapeutics++++For%3A+Jun+30/26898650.html Mon, 10 Aug 2026 16:38:00 -0400 DMAC O.02595765 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DiaMedica+Therapeutics++++For%3A+Jun+30/26898650.html si-local-file:///var/storage/secattach/20260810/26898650.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DiaMedica+Therapeutics++++For%3A+Jun+30/26898650.html Mon, 10 Aug 2026 16:38:00 -0400 DMAC O.02595765 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DiaMedica+Therapeutics++++For%3A+Aug+10/26898607.html si-local-file:///var/storage/secattach/20260810/26898607.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DiaMedica+Therapeutics++++For%3A+Aug+10/26898607.html Mon, 10 Aug 2026 16:36:00 -0400 DMAC O.02595765 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DiaMedica+Therapeutics++++For%3A+Aug+10/26898607.html si-local-file:///var/storage/secattach/20260810/26898607.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DiaMedica+Therapeutics++++For%3A+Aug+10/26898607.html Mon, 10 Aug 2026 16:36:00 -0400 DMAC O.02595765 http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Press+Releases/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537 http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html <ul class="bwlistdisc"> <li> <b><i>Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September</i></b> </li> <li> <b><i>Positive Topline Results from Phase 2 Late-Onset Preeclampsia Part 1a Dose-Extension Cohort, Demonstrating Rapid, Clinically Meaningful, and Statistically Significant Reductions in Maternal Blood Pressure</i></b> </li> <li> <b><i>Enrollment for Acute Ischemic Stroke Phase 2/3 Trial Progressing with Interim Analysis Anticipated Q1 2027</i></b> </li> <li> <b><i>$43.5 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027</i></b> </li> <li> <b><i>Conference Call and Webcast August 11 at 8:00 AM Eastern Time / 7:00 AM Central Time</i></b> </li> </ul> <p> MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage http://www.streetinsider.com/Business+Wire/DiaMedica+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Highlights/26898443.html Mon, 10 Aug 2026 16:30:00 -0400 A.06822034 A.17150087 A.50216777 DMAC O.02595765 O.20026344 O.34929518 O.54516537